Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
NEW YORK, July 14, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Roche Holding AG ("Roche Holding") (OTCMKTS:RHHBY) securities between March 2, 2017 and June 5, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/roche-holding-ag?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) the combination of Perjeta and Herceptin is only marginally more effective than Herceptin alone in preventing breast cancer; and (2) as a result, Defendants' statements about Roche Holding AG's business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times.
If you suffered a loss in Roche Holding you have until August 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/roche-holding-ag?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
